SLIDES
1. Regeneus
2. Important Notice
3. 5 Reasons to Look at Regeneus
4. 4th Therapeutic Pillar of Healthcare
5. Regenerative Medicine Markets are Large and Growing Rapidly
6. Pipeline Summary
7. Progenza - Leading Off-the-Shelf Stem Cell Platform
8. Progenza - Why MSC Secretions Matter
9. Progenza – Phase 1 for OA Primary Endpoints Met
10. Progenza – Phase 1 for OA Significant Secondary Endpoints
11. Collaboration with AGC of Japan for Progenza
12. Japan is Leading RM Corporate Activity
13. Sygenus - Emerging MSC Secretions Technology Platform
14. Sygenus Shows Promise in Pain Model v Morphine
15. Patent Portfolio Update
16. Licensing Driven Business Model
17. Financials and Share Performance
18. Outlook for FY18
19. Further Information
Regeneus (ASX.RGS), Finance News Network Investor Event Small Cap Showcase, October 2017.pdf
1 / 19